- Home
- ABVC vs VERU Comparison
ABVC vs VERU Comparison
Compare ABVC & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- VERU
- Stock Information
- Founded
- ABVC 2015
- VERU 1971
- Country
- ABVC United States
- VERU United States
- Employees
- ABVC N/A
- VERU N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- VERU Health Care
- Exchange
- ABVC Nasdaq
- VERU Nasdaq
- Market Cap
- ABVC 52.1M
- VERU 54.6M
- IPO Year
- ABVC N/A
- VERU 1990
- Fundamental
- Price
- ABVC $2.77
- VERU $3.50
- Analyst Decision
- ABVC
- VERU Strong Buy
- Analyst Count
- ABVC 0
- VERU 3
- Target Price
- ABVC N/A
- VERU $33.33
- AVG Volume (30 Days)
- ABVC 84.1K
- VERU 139.0K
- Earning Date
- ABVC 11-13-2025
- VERU 12-15-2025
- Dividend Yield
- ABVC N/A
- VERU N/A
- EPS Growth
- ABVC N/A
- VERU N/A
- EPS
- ABVC N/A
- VERU N/A
- Revenue
- ABVC $391,242.00
- VERU $16,886,419.00
- Revenue This Year
- ABVC $735.18
- VERU N/A
- Revenue Next Year
- ABVC N/A
- VERU N/A
- P/E Ratio
- ABVC N/A
- VERU N/A
- Revenue Growth
- ABVC 186.84
- VERU 337.24
- 52 Week Low
- ABVC $0.40
- VERU $2.64
- 52 Week High
- ABVC $5.48
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- ABVC 47.60
- VERU 47.71
- Support Level
- ABVC $2.86
- VERU $3.61
- Resistance Level
- ABVC $3.05
- VERU $3.99
- Average True Range (ATR)
- ABVC 0.15
- VERU 0.30
- MACD
- ABVC -0.02
- VERU -0.10
- Stochastic Oscillator
- ABVC 26.59
- VERU 14.52
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.